• 1) Laghi F, Langbein WE, Antonescu-Turcu A, Jubran A, Bammert C, Tobin MJ. Respiratory and skeletal muscles in hypogonadal men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:598-605
• 2) Laghi F, Antonescu-Turcu A, Collins E, Segal J, Tobin DE, Jubran A, Tobin MJ. Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life. Am J Respir Crit Care Med 2005;171:728-733
• 3) Fishman AP. One Hundred Years of COPD. Am J Respir Crit Care Med 2005; 171:941-948
• 4) Takabatake N, Sata M, Inoue S, Shibata Y, Abe S, Wada T, Machiya J, Ji G, Matsuura T, Takeishi Y, Muramatsu M, Kubota I. A novel polymorphism in secretory phospholipase A2-IID is associated with body weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:1097-1104
• Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, Ehrhart M, Kessler R, Weitzenblum E. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189-194
• 6) Saey D, Michaud A, Couillard A, Cote CH, Mador MJ, LeBlanc P, Jobin J, Maltais F. Contractile fatigue, muscle morphometry, and blood lactate in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:1109-1115
• 7) Van Vliet M, Spruit MA, Verleden G, Kasran A, Van Herck E, Pitta F, Bouillon R, Decramer M. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:1105-1111
• 8) Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. Jama 2005;294:716-724
• 9) Koechlin C, Maltais F, Saey D, Michaud A, LeBlanc P, Hayot M, Prefaut C. Hypoxaemia enhances peripheral muscle oxidative stress in chronic obstructive pulmonary disease. Thorax 2005;60:834-841
• 10) Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:367-70; discussion 371-372
• 11) Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128 (4): 2099-2107
• 12) Global Initiative for Chronic Obstructive Lung Disease. Update 1 July 2005. A collaborative project of the National Health L, and Blood Institute, NIH and the World Health Organisation., ed. www.goldcopd.org National Institutes of Health, National Heart Lund and Blood Institute, Bethesda, Md, 2005.
• 13) Shapiro SD. COPD Unwound. N Engl J Med 2005; 352(19): 2016-2019
• 14) Mannino D. Chronic obstructive pulmonary disease in 2025: where are we headed. Eur Respir J 2005; 26: 189
• 15) Sin DD. and Man SF. Chronic Obstructive Pulmonary Disease as a Risk Factor for Cardiovascular Morbidity and Mortality. Proc Am Thorac Soc Vol 2. pp 8–11, 2005
• 16) Donald B. Hunninghake. Cardiovascular Disease in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc Vol 2. pp 44–49, 2005
• 17) Semenza GL. Pulmonary Vascular Responses to Chronic Hypoxia Mediated by Hypoxia-inducible Factor 1. Proc Am Thorac Soc Vol 2. pp 68–70, 2005
• 18) Agusti AG, Noguera A., Sauleda J., Sala E., Pons J., Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347–360
• 19) Gan WQ, Man SF, Senthilselvan A and Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574–580.
• 20) Wouters EF. Introduction: systemic effects in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: Suppl. 46, 1s.
• 21) Higenbottam T. Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc Vol 2. pp 12–19, 2005
• 22) Wouters EF. Local and Systemic Inflammation in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc Vol 2. pp 26–33, 2005
• 23) MacNee W. Pulmonary and Systemic Oxidant/Antioxidant Imbalance in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc Vol 2. pp 50–60, 2005
• 24) Tapson VF. The Role of Smoking in Coagulation and Thromboembolism in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc Vol 2. pp 71–77, 2005
• 25) Rennard SI. Clinical Approach to Patients with Chronic Obstructive Pulmonary Disease and Cardiovascular Disease. Proc Am Thorac Soc Vol 2. pp 94–100, 2005
• 26) Mannino DM., Doherty DE., Buist AS. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. In press
• 27) Sin DD. and Man SF. Can inhaled steroids mend a broken heart in chronic obstructive pulmonary disease? Eur Respir J 2005; 25: 589–590
• 28) Naeije R. Pulmonary Hypertension and Right Heart Failure in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc Vol 2. pp 20–22, 2005
• 29) MacCallum PK. Markers of Hemostasis and Systemic Inflammation in Heart Disease and Atherosclerosis in Smokers. Proc Am Thorac Soc Vol 2. pp 34–43, 2005
• 30) van Eeden SF., Yeung A, Quinlam K, and Hogg JC. Systemic Response to Ambient Particulate Matter Relevance to Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc Vol 2. pp 61–67, 2005
• 31) Man SF and Sin DD.. Effects of Corticosteroids on Systemic Inflammation in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc Vol 2. pp 78–82, 2005
• 32) Celli BR., Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, and Cabral HJ. The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease. N Engl J Med 2004;350:1005-12.
• 33) Sunyer J. and Ulrik CS. Level of FEV1 as a predictor of all-cause and cardiovascular mortality: an effect beyond smoking and physical fitness? Eur Respir J 2005; 25: 587–588
• 34) Huiart L, Ernst P, Ranouil X and Suissa S. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005; 25: 634–639
• 35) Stavem K, Aaser E, Sandvik L, Bjørnholt JV, Erikssen G, Thaulow E and Erikssen J. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. Eur Respir J 2005; 25: 618–625
• Altre pubblicazioni [PDF]

• 1) Kim DS, Kim YS, Jung KS, Chang JH, Lim CM, Lee JH, Uh ST, Shim JJ, Lew WJ. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med 2005;172:842-847
• 2) Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-239
• 3) Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004;364:613-620
• 4) Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, Valdivia G, Montes de Oca M, Talamo C, Hallal PC, Victora CG. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005;366:1875-1881
• 5) Wood S, Norboo T, Lilly M, Yoneda K, Eldridge M. Cardiopulmonary function in high altitude residents of Ladakh. High Alt Med Biol 2003;4:445-454
• 6) Havryk AP, Gilbert M, Burgess KR. Spirometry values in Himalayan high altitude residents (Sherpas). Respir Physiol Neurobiol 2002;132:223-232
• 7) Global Initiative for Chronic Obstructive Lung Disease. Update 1 July 2005. A collaborative project of the National Health L, and Blood Institute, NIH and the World Health Organisation., ed. www.goldcopd.org: National Institutes of Health, National Heart Lund and Blood Institute, Bethesda, Md, 2005.
• Altre pubblicazioni [PDF]

• 1) Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Moore M, Sullivan A, Nicolls MR, Fontenot AP, Tuder RM, Voelkel NF. An animal model of autoimmune emphysema. Am J Respir Crit Care Med 2005;171:734-742
• 2) Santus P, Sola A, Carlucci P, Fumagalli F, Di Gennaro A, Mondoni M, Carnini C, Centanni S, Sala A. Lipid peroxidation and 5-lipoxygenase activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:838-843
• 3) Taggart CC, Greene CM, Carroll TP, O'Neill SJ, McElvaney NG. Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease. Am J Respir Crit Care Med 2005;171:1070-1076
• 4) Lundblad LK, Thompson-Figueroa J, Leclair T, Sullivan MJ, Poynter ME, Irvin CG, Bates JH. Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype. Am J Respir Crit Care Med 2005;171:1363-1370
• 5) Sullivan AK, Simonian PL, Falta MT, Mitchell JD, Cosgrove GP, Brown KK, Kotzin BL, Voelkel NF, Fontenot AP. Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Am J Respir Crit Care Med 2005;172:590-596
• 6) Isao Ito, Sonoko Nagai, Tomohiro Handa, Shigeo Muro, Toyohiro Hirai, Mitsuhiro Tsukino, and Michiaki Mishima Matrix Metalloproteinase-9 Promoter Polymorphism Associated with Upper Lung Dominant Emphysema Am. J. Respir. Crit. Care Med.2005; 172: 1378-1382
• 7) Woodruff PG, Koth LL, Yang YH, Rodriguez MW, Favoreto S, Dolganov GM, Paquet AC, Erle DJ. A distinctive alveolar macrophage activation state induced by cigarette smoking. Am J Respir Crit Care Med 2005;172:1383-1392
• 8) Ingenito EP, Tsai LW, Majumdar A, Suki B. On the role of surface tension in the pathophysiology of emphysema. Am J Respir Crit Care Med 2005;171:300-304
• 9) van Diemen CC, Postma DS, Vonk JM, Bruinenberg M, Schouten JP, Boezen HM. A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am J Respir Crit Care Med 2005;172:329-333
• 10) Mannino DM , Watt G, Hole D, Gillis C, Hart C, McConnachie A, Davey Smith G, Uptone M, Hawthorne V, Sin DD, Man SFP, Van Eeden S, Mapel DW and Vestbo J. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 627–643
• 11) Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005;60:293-300
• 12) Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F, Cavallesco G, Tropeano G, Mapp CE, Maestrelli P, Ciaccia A, Fabbri LM. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:711-717
• 13) Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53
• 14) Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:26-33
• 15) MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:50-60
• 16) Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res 2001;2:20-26
• 17) Jongepier H, Boezen HM, Dijkstra A, Howard TD, Vonk JM, Koppelman GH, Zheng SL, Meyers DA, Bleecker ER, Postma DS. Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma. Clin Exp Allergy 2004;34:757-760
• 18) Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-721
• 19) Kelleher CM, Silverman EK, Broekelmann T, Litonjua AA, Hernandez M, Sylvia JS, Stoler J, Reilly JJ, Chapman HA, Speizer FE, Weiss ST, Mecham RP, Raby BA. A functional mutation in the terminal exon of elastin in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2005;33:355-362
• 20) Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax 2005;60:605-9
• 21) Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-9
• 22) Tsoumakidou M, Tzanakis N, Chrysofakis G, Siafakas NM. Nitrosative stress, heme oxygenase-1 expression and airway inflammation during severe exacerbations of COPD. Chest 2005;127:1911-1918
• 23) Global Initiative for Chronic Obstructive Lung Disease. Update 1 July 2005. A collaborative project of the National Health L, and Blood Institute, NIH and the World Health Organisation., ed. www.goldcopd.com: National Institutes of Health, National Heart Lund and Blood Institute, Bethesda, Md, 2005. 2005
• 24) Voelkel N, Taraseviciene-Stewart L. Emphysema An Autoimmune Vascular Disease? Proc Am Thorac Soc Vol 2. pp 23–25, 2005
• 25) James C. Hogg, M.D., Fanny Chu, B.Sc., Soraya Utokaparch, B.Sc., Ryan Woods, M.Sc., W. Mark Elliott, Ph.D., Liliana Buzatu, M.D., Ruben M. Cherniack, M.D., Robert M. Rogers, M.D., Frank C. Sciurba, M.D., Harvey O. Coxson, Ph.D., and Peter D. Paré, M.D. The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease. N Engl J Med 2004;350:2645-53.
• gold_sk_2005_clean.ppt
• Altre pubblicazioni [PDF]

4. Fattori di rischio

• 1) McKeever TM, Lewis SA, Smit HA, Burney P, Britton JR, Cassano PA. The association of acetaminophen, aspirin, and ibuprofen with respiratory disease and lung function. Am J Respir Crit Care Med 2005;171:966-971
• 2) van Diemen CC, Postma DS, Vonk JM, Bruinenberg M, Schouten JP, Boezen HM. A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am J Respir Crit Care Med 2005;172:329-333
• 3) Isao Ito, Sonoko Nagai, Tomohiro Handa, Shigeo Muro, Toyohiro Hirai, Mitsuhiro Tsukino, and Michiaki Mishima Matrix Metalloproteinase-9 Promoter Polymorphism Associated with Upper Lung Dominant Emphysema Am. J. Respir. Crit. Care Med.2005; 172: 1378-1382
• 4) Takabatake N, Sata M, Inoue S, Shibata Y, Abe S, Wada T, Machiya J, Ji G, Matsuura T, Takeishi Y, Muramatsu M, Kubota I. A novel polymorphism in secretory phospholipase A2-IID is associated with body weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:1097-1104
• 5) Woodruff PG, Koth LL, Yang YH, Rodriguez MW, Favoreto S, Dolganov GM, Paquet AC, Erle DJ. A distinctive alveolar macrophage activation state induced by cigarette smoking. Am J Respir Crit Care Med 2005;172:1383-1392
• 6) Richmond RJ, Zellner KM. Alpha1-antitrypsin deficiency: incidence and implications. Dimens Crit Care Nurs 2005; 24 (6): 255-260
• 7) Senn O, Russi EW, Imboden M, Probst-Hensch NM. Alpha1-antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants. Eur Respir J 2005; 26 (5): 909-917
• 8) De la Roza C, Rodriguez-Frias F, Lara B, Vidal R, Jardi R, Miravitlles M. Results of a case-detection programme for alpha1-antitrypsin deficiency in COPD patients. Eur Respir J 2005; 26 (4): 616-622
• 9) Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003. Chest 2005; 128 (3): 1179-1186
• 10) Wewers MD. Alpha1-antitrypsin deficiency: more than a protease imbalance? Chest 2004; 125 (5): 1607-1609
• 11) De Meo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004; 59 (3): 259-264
• 12) Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG, Silverman EK. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax 2004 59(10): 843-849
• 13) Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-9
• 14) Willemse BW, Postma DS, Timens W, ten Hacken NH. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004;23:464-76
• 15) MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:50-60
• 16) Denicola A, Radi R. Peroxynitrite and drug-dependent toxicity. Toxicology 2005;208:273-88
• 17) Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res 2001;2:20-6
• 18) Jongepier H, Boezen HM, Dijkstra A, Howard TD, Vonk JM, Koppelman GH, Zheng SL, Meyers DA, Bleecker ER, Postma DS. Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma. Clin Exp Allergy 2004;34:757-60
• 19) Kelleher CM, Silverman EK, Broekelmann T, Litonjua AA, Hernandez M, Sylvia JS, Stoler J, Reilly JJ, Chapman HA, Speizer FE, Weiss ST, Mecham RP, Raby BA. A functional mutation in the terminal exon of elastin in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2005;33:355-62
• 20) Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12
• 21) Ong KC, Earnest A, Lu SJ. A multidimensional grading system (BODE index) as predictor of hospitalization for COPD. Chest 2005;128:3810-6
• 22) Global Initiative for Chronic Obstructive Lung Disease. Update 1 July 2005. A collaborative project of the National Health L, and Blood Institute, NIH and the World Health Organisation., ed. www.goldcopd.org: National Institutes of Health, National Heart Lund and Blood Institute, Bethesda, Md, 2005. 2005
• Altre pubblicazioni [PDF]

• 1) Saey D, Michaud A, Couillard A, Cote CH, Mador MJ, LeBlanc P, Jobin J, Maltais F. Contractile fatigue, muscle morphometry, and blood lactate in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:1109-1115
• 2) Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:591-597
• 3) Barreiro E, de la Puente B, Minguella J, Corominas JM, Serrano S, Hussain SN, Gea J. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:1116-1124
• 4) Ottenheijm CA, Heunks LM, Sieck GC, Zhan WZ, Jansen SM, Degens H, de Boo T, Dekhuijzen PN. Diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:200-20
• 5) Busse WW, Wanner A, Adams K, Reynolds HY, Castro M, Chowdhury B, Kraft M, Levine RJ, Peters SP, Sullivan EJ. Investigative bronchoprovocation and bronchoscopy in airway diseases. Am J Respir Crit Care Med 2005;172: 807-816
• 6) Stevenson NJ, Walker PP, Costello RW, Calverley PM. Lung Mechanics and Dyspnea during Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2005;172:1510-1516
• 7) Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946
• 8) Cerveri I, Dore R, Corsico A, Zoia MC, Pellegrino R, Brusasco V, Pozzi E. Assessment of emphysema in COPD: a functional and radiologic study. Chest 2004;125:1714-8
• 9) Lapperre TS, Snoeck-Stroband JB, Gosman MM, Stolk J, Sont JK, Jansen DF, Kerstjens HA, Postma DS, Sterk PJ. Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:499-504
• 10) Global Initiative for Chronic Obstructive Lung Disease. Update 1 July 2005. A collaborative project of the National Health L, and Blood Institute, NIH and the World Health Organisation., ed. www.goldcopd.org : National Institutes of Health, National Heart Lund and Blood Institute, Bethesda, Md, 2005. 2005
• 11) Brusasco V, Crapo R, Viegi G. Coming together: the ATS/ERS consensus on clinical pulmonary function testing. Eur Respir J 2005; 26: 1-2
• 12) Miller MR, Crapo R, Hankinson J, Brusasco V, Brurgos F, Casaburi R, Coates A, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johson DC, Mac Intyre N, Mc Kay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. General considerations for lung function testing. Eur Respir J 2005; 26: 153-161
• 13) Akero A, Christensen CC, Edvardsen A, Skjonsberg OH. Hypoxaemia in chronic obstructive pulmonary disease patients during a commercial flight. Eur Respir J 2005; 25: 725-730
• gold-Modena2006-Maestrelli.ppt
• Altre pubblicazioni [PDF]

• 1) Nakano Y, Wong JC, de Jong PA, Buzatu L, Nagao T, Coxson HO, Elliott WM, Hogg JC, Pare PD. The prediction of small airway dimensions using computed tomography. Am J Respir Crit Care Med 2005;171:142-146
• 2) Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, Ehrhart M, Kessler R, Weitzenblum E. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189-194
• 3) Orlandi I, Moroni C, Camiciottoli G, Bartolucci M, Pistolesi M, Villari N, Mascalchi M. Chronic obstructive pulmonary disease: thin-section CT measurement of airway wall thickness and lung attenuation. Radiology 2005; 234 (2): 604-610
• 4) Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46
• 5) Cerveri I, Dore R, Corsico A, Zoia MC, Pellegrino R, Brusasco V, Pozzi E. Assessment of emphysema in COPD: a functional and radiologic study. Chest 2004;125:1714-8
• 6) Lapperre TS, Snoeck-Stroband JB, Gosman MM, Stolk J, Sont JK, Jansen DF, Kerstjens HA, Postma DS, Sterk PJ. Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:499-504
• 7) Global Initiative for Chronic Obstructive Lung Disease. Update 1 July 2005. A collaborative project of the National Health L, and Blood Institute, NIH and the World Health Organisation., ed. www.goldcopd.org : National Institutes of Health, National Heart Lund and Blood Institute, Bethesda, Md, 2005. 2005
• gold_IT_2006.ppt
• Altre pubblicazioni [PDF]

• Modena1.ppt

• 1) Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-9
• 2) Willemse BW, Postma DS, Timens W, ten Hacken NH. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004;23:464-76
• 3) Global Initiative for Chronic Obstructive Lung Disease. Update 1 July 2005. A collaborative project of the National Health L, and Blood Institute, NIH and the World Health Organisation., ed. www.goldcopd.org : National Institutes of Health, National Heart Lund and Blood Institute, Bethesda, Md, 2005. 2005
• Corbetta.ppt
• Fumo GOLD 2006 Nutini.ppt
• Fumo GOLD 2006 Sabato.ppt
• Altre pubblicazioni [PDF]

• 1) Birrell MA, Wong S, Hele DJ, McCluskie K, Hardaker E, Belvisi MG. Steroid-resistant inflammation in a rat model of chronic obstructive pulmonary disease is associated with a lack of nuclear factor-kappaB pathway activation. Am J Respir Crit Care Med 2005;172:74-84
• 2) Kiri VA, Pride NB, Soriano JB, Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 2005;172:460-464
• 3) van der Vaart H, Koeter GH, Postma DS, Kauffman HF, ten Hacken NH. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:465-469
• 4) Murakami S, Nagaya N, Itoh T, Iwase T, Fujisato T, Nishioka K, Hamada K, Kangawa K, Kimura H. Adrenomedullin regenerates alveoli and vasculature in elastase-induced pulmonary emphysema in mice. Am J Respir Crit Care Med 2005;172:581-589
• 5) Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005;172:848-853
• 6) Lee JH, Lee DS, Kim EK, Choe KH, Oh YM, Shim TS, Kim SE, Lee YS, and Lee SD Simvastatin Inhibits Cigarette Smoking–induced Emphysema and Pulmonary Hypertension in Rat Lungs Am. J. Respir. Crit. Care Med. 2005; 172: 987-993.
• 7) Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK. Anti-inflammatory effects of salmeterol/ fluticasone propionate in chronic obstructive lung disease. In press
• 8) Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005;365:1552-60
• 9) Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004;363:731-3
• 10) Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352:1967-76
• 11) Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005;25:1084-106.
• 12) Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005;25:552-63
• 13) Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005;16:624-629
• 14) Lee SD, Lee JH, Kim EK, Choi KH, Oh YM, Shim TS. Effects of simvastatin on cigarette smoking-induced structural and functional changes in rat lungs. Chest 2005;128:574S
• 15) Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, Kesten S, O'Donnell D. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005;128:1168-78
• 16) O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-40
• 17) Donohue JF. Therapeutic responses in asthma and COPD. Bronchodilators. Chest 2004;126:125S-137S; discussion 159S-161S
• 18) Pepin V, Saey D, Whittom F, Leblanc P, Maltais F. Walking versus Cycling: Sensitivity to Bronchodilation in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2005;172:1517-22
• 19) Higenbottam T. Pulmonary hypertension and chronic obstructive pulmonary disease: a case for treatment. Proc Am Thorac Soc 2005;2:12-9
• 20) Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax 2005;60:605-9
• 21) Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46
• 22) Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81
• 23) Calverley PM, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56
• 24) Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-9
• 25) Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA, Jr., Korducki L, Cassino C, Kesten S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143:317-26
• 26) van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005;26:214-22
• 27) Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73
• 28) Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Lindmark B, Pauwels RA, Postma DS, Soriano JB, Szafranski W, Vestbo J. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005;60:992-7
• 29) Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005;365:167-75
• 30) Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-71
• 31) Fitzgerald JM, Boulet LP, Follows RM. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther. 2005; 27 (4): 393-406
• 32) Global Initiative for Chronic Obstructive Lung Disease. Update 1 July 2005. A collaborative project of the National Health L, and Blood Institute, NIH and the World Health Organisation., ed. www.goldcopd.org: National Institutes of Health, National Heart Lund and Blood Institute, Bethesda, Md, 2005.
• 33) van noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJG. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26:214-222
• 34) Buhl Roland and Farmer SG.. Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc Vol 2. pp 83–93, 2005
• 35) Alfageme I, Vazquez R, Reyes N, Muñoz J, Fernández A, Hernandez M, Merino M, Perez J, Lima J Clinical efficacy of anti-pneumococcal vaccination in patients with COPD Thorax 2006;61;189-195; originally published online 14 Oct 2005; doi:10.1136/thx.2005.043323
• 36) Dusser D, Bravo M-L, Iacono P The effect of tiotropium on exacerbations and airflow in patients with COPD Eur Respir J 2006; 27: 547–555 DOI: 10.1183/09031936.teroids in Chronic Obstructive Pulmonary Disease: Misconstrued Immortal Time Bias
• 06.00062705 Copyright
  ERS Journals Ltd 2006
• 37) Sin DD, Wu L, J A Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Lindmark B, Pauwels RA, Postma DS, Soriano JB, Szafranski W, Vestbo J Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease Thorax 2005;60;992-997; originally published online 14 Oct 2005; doi:10.1136/thx.2005.045385
• 38) Suissa S STATISTICAL TREATMENT OF EXACERBATIONS IN THERAPEUTIC TRIALS OF COPD AJRCCM Articles Published on January 26, 2006 as doi:10.1164/rccm.200508-1338PP in Press.
• 39) Suissa S Observational Studies of Inhaled Corticos
• Altre pubblicazioni [PDF]

• 1) Kim V, Criner GJ, Abdallah HY, Gaughan JP, Furukawa S, Solomides CC. Small airway morphometry and improvement in pulmonary function after lung volume reduction surgery. Am J Respir Crit Care Med 2005;171:40-47
• 2) Hopkinson NS, Toma TP, Hansell DM, Goldstraw P, Moxham J, Geddes DM, Polkey
• 3) MI. Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med 2005;171:453-460
• 4) Fishman AP. One Hundred Years of COPD. Am J Respir Crit Care Med 2005; 171: 941-948
• 5) Shigemura N, Sawa Y, Mizuno S, Ono M, Minami M, Okumura M, Nakamura T, Kaneda Y, Matsuda H. Induction of compensatory lung growth in pulmonary emphysema improves surgical outcomes in rats. Am J Respir Crit Care Med 2005;171:1237-1245
• 6) Troosters T, Casaburi R, Gosselink R, Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:19-38
• 7) Ottenheijm CA, Heunks LM, Sieck GC, Zhan WZ, Jansen SM, Degens H, de Boo T, Dekhuijzen PN. Diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:200-205
• 8) Guyatt GH, Nonoyama M, Lacchetti C, Goeree R, McKim D, Heels-Ansdell D, Goldstein R. A randomized trial of strategies for assessing eligibility for long-term domiciliary oxygen therapy. Am J Respir Crit Care Med 2005;172: 573-580
• 9) Mercken EM, Hageman GJ, Schols AM, Akkermans MA, Bast A, Wouters EF. Rehabilitation decreases exercise-induced oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:994-1001
• 10) Gorman RB, McKenzie DK, Butler JE, Tolman JF, Gandevia SC. Diaphragm length and neural drive after lung volume reduction surgery. Am J Respir Crit Care Med 2005;172:1259-1266
• 11) Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46
• 12) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980;93:391-8
• 13) Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981;1:681-6
• 14) Macnee W. Prescription of oxygen: still problems after all these years. Am J Respir Crit Care Med 2005;172:517-8
• 15) Ramsey SD, Berry K, Etzioni R, Kaplan RM, Sullivan SD, Wood DE. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med 2003;348:2092-102
• 16) Global Initiative for Chronic Obstructive Lung Disease. Update 1 July 2005. A collaborative project of the National Health L, and Blood Institute, NIH and the World Health Organisation., ed. www.goldcopd.org: National Institutes of Health, National Heart Lund and Blood Institute, Bethesda, Md, 2005.
• 17) Vogiatzis I, Terzis G, Nanas S, Stratakos G, Simoes DC, Georgiadou O, Zakynthinos S, Roussos C. Skeletal muscle adaptations to interval training in patients with advanced COPD. Chest 2005;128(6):3838-3845.
• 18) Pang SM, Chan KS, Chung BP, Lau KS, Leung EM, Leung AW, Chan HY, Chan TM. Assessing quality of life of patients with advanced chronic obstructive pulmonary disease in the end of life. J Palliat Care 2005;21(3):180-187.
• 19) Riario-Sforza GG, Incorvaia C, Paterniti F, Dugnani N, Fumagalli M. Different outcomes of pulmonary rehabilitation in patients with COPD with or without exacerbations. Monaldi Arch Cest Dis 2005;63(3):129-132.
• 20) Hillerdal G, Lofdahl CG, Strom K, Skoogh BE, Jorfeldt L, Nilsson F, Forslund-Stiby D, Ranstam J, Gyllstedt E. Comparison of lung volume reduction surgery and physical training on health status and physiologic outcomes: a randomized controlled clinical trial. Chest 2005;128(5):3489-3499.
• 21) Spruit MA, Gosselink R, Troosters T, Kasran A, van Vliet M, Decramer M. Low-grade systemic inflammation and the response to exercise training in patients with advanced COPD. Chest 2005;128(5):3183-3190
• 22) Gadoury MA, Schwartzman K, Rouleau M, Maltais F, Julien M, Beaupre A, Renzi P, Begin R, Nault D, Bourbeau J. Self-management reduces both short- and long-term hospitalisation in COPD; Chronic Obstructive Pulmonary Disease axis of the Respiratory Health Network, Fonds de la recherche en sante du Quebec (FRSQ). Eur Respir J 2005;26(5):853-857
• 23) Porta R, Vitacca M, Gile LS, Clini E, Bianchi L, Zanotti E, Ambrosino N. Supported arm training in patients recently weaned from mechanical ventilation. Chest 2005 ;128(4):2511-2520.
• 24) Carrieri-Kohlman V, Nguyen HQ, Donesky-Cuenco D, Demir-Deviren S, Neuhaus J, Stulbarg MS. Impact of brief or extended exercise training on the benefit of a dyspnea self-management program in COPD. J Cardiopulm Rehabil 2005;25(5):275-284.
• 25) Pitta F, Troosters T, Spruit MA, Decramer M, Gosselink R. Activity monitoring for assessment of physical activities in daily life in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2005;86(10):1979-1985.
• 26) Favret F, Henderson KK, Allen J, Richalet JP, Gonzalez NC. Exercise training improves lung gas exchange and attenuates acute hypoxic pulmonary hypertension but does not prevent pulmonary hypertension of prolonged hypoxia. J Appl Physiol 2006;100(1):20-25. Epub 2005 Sep 22.
• 27) Gigliotti F, Coli C, Bianchi R, Grazzini M, Stendardi L, Castellani C, Scano G. Arm exercise and hyperinflation in patients with COPD: effect of arm training. Chest 2005;128(3):1225-1232.
• 28) Mador MJ, Deniz O, Aggarwal A, Shaffer M, Kufel TJ, Spengler CM. Effect of respiratory muscle endurance training in patients with COPD undergoing pulmonary rehabilitation. Chest 2005;128(3):1216-1224.
• 29) Sewell L, Singh SJ, Williams JE, Collier R, Morgan MD. Can individualized rehabilitation improve functional independence in elderly patients with COPD?. Chest 2005;128(3):1194-1200.
• 30) Mackay MR, Ellis E, Johnston C. Randomised clinical trial of physiotherapy after open abdominal surgery in high risk patients. Aust J Physiother 2005;51(3):151-159.
• 31) Verrill D, Barton C, Beasley W, Lippard WM. The effects of short-term and long-term pulmonary rehabilitation on functional capacity, perceived dyspnea, and quality of life. Chest 2005;128(2):673-683.
• 32) Mercken EM, Hageman GJ, Schols AM, Akkermans MA, Bast A, Wouters EF. Rehabilitation decreases exercise-induced oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005 15;172(8):994-1001. Epub 2005 Jul 22.
• 33) Grill E, Huber EO, Stucki G, Herceg M, Fialka-Moser V, Quittan M. Identification of relevant ICF categories by patients in the acute hospital. Disabil Rehabil 2005 8-22;27(7-8):447-458.
• 34) Bjornshave B, Korsgaard J. Comparison of two different levels of physical training in patients with moderate to severe COPD. Lung 2005;183(2):101-108.
• 35) Wadell K, Henriksson-Larsen K, Lundgren R, Sundelin G. Group training in patients with COPD - long-term effects after decreased training frequency. Disabil Rehabil 2005 20;27(10):571-581.
• 36) Maltais F, Bourbeau J, Lacasse Y, Shapiro S, Perrault H, Penrod JR, Baltzan M, Rouleau M, Julien M, Paradis B, Audet R, Hernandez P, Levy RD, Camp P, Lecours R, Picard D, Bernard S. A Canadian, multicentre, randomized clinical trial of home-based pulmonary rehabilitation in chronic obstructive pulmonary disease: rationale and methods. Can Respir J 2005;12(4):193-198.
• 37) Sandland CJ, Singh SJ, Curcio A, Jones PM, Morgan MD. A profile of daily activity in chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005;25(3):181-183.
• 38) Behnke M, Wewel AR, Kirsten D, Jorres RA, Magnussen H. Exercise training raises daily activity stronger than predicted from exercise capacity in patients with COPD. Respir Med 2005;99(6):711-717. Epub 2005 Jan 18.
• 39) Ringbaek TJ, Lange P. Outdoor activity and performance status as predictors of survival in hypoxaemic chronic obstructive pulmonary disease (COPD). Clin Rehabil 2005;19(3):331-338.
• 40) Incalzi RA, Corsonello A, Pedone C, Corica F, Carbonin P, Bernabei R; GIFA Investigators. Construct validity of activities of daily living scale: a clue to distinguish the disabling effects of COPD and congestive heart failure. Chest 2005;127(3):830-838.
• 41) Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;127(3):809-817.
• 42) Bauldoff GS, Rittinger M, Nelson T, Doehrel J, Diaz PT. Feasibility of distractive auditory stimuli on upper extremity training in persons with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005;25(1):50-55.
• 43) Plankeel JF, McMullen B, MacIntyre NR. Exercise outcomes after pulmonary rehabilitation depend on the initial mechanism of exercise limitation among non-oxygen-dependent COPD patients. Chest 2005;127(1):110-116.
• 44) Rossi G, Florini F, Romagnoli M, Bellantone T, Lucic S, Lugli D, Clini E. Length and clinical effectiveness of pulmonary rehabilitation in outpatients with chronic airway obstruction. Chest 2005;127(1):105-109.
• Altre pubblicazioni [PDF]

• 1) Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:446-452
• 2) Chin CL, Manzel LJ, Lehman EE, Humlicek AL, Shi L, Starner TD, Denning GM, Murphy TF, Sethi S, Look DC. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med 2005;172:85-91
• 3) Murphy TF, Brauer AL, Grant BJ, Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005;172:195-199
• 4) Stevenson NJ, Walker PP, Costello RW, Calverley PM. Lung Mechanics and Dyspnea during Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2005;172:1510-1516
• 5) Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005;60:293-300
• 6) Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946
• 7) Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, Reznek RH, Wedzicha JA. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:400-407
• 8) Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-931
• 9) Sethi S. Pathogenesis and treatment of acute exacerbations of chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005;26:192-203
• 10) Conrad C. Does bacterial colonization play a role in acute respiratory failure in chronic obstructive pulmonary disease? Crit Care Med 2005;33:2130-2131
• 11) Murphy TF, Brauer AL, Grant BJ, Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005;172:195-199
• 12) Chin CL, Manzel LJ, Lehman EE, Humlicek AL, Shi L, Starner TD, Denning GM, Murphy TF, Sethi S, Look DC. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med 2005;172:85-91
• 13) Rosell A, Monso E, Soler N, Torres F, Angrill J, Riise G, Zalacain R, Morera J, Torres A. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005;165:891-897
• 14) Beckham JD, Cadena A, Lin J, Piedra PA, Glezen WP, Greenberg SB, Atmar RL. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect 2005;50:322-330
• 15) McManus TE, Coyle PV, Kidney JC. Childhood respiratory infections and hospital admissions for COPD. Respir Med 2005
• 16) Stevenson NJ, Walker PP, Costello RW, Calverley PM. Lung Mechanics and Dyspnea during Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2005;172:1510-1516
• 17) Global Initiative for Chronic Obstructive Lung Disease. Update 1 July 2005. A collaborative project of the National Health L, and Blood Institute, NIH and the World Health Organisation., ed. www.goldcopd.org : National Institutes of Health, National Heart Lund and Blood Institute, Bethesda, Md, 2005. 2005
• diagnosi e gestione riacutizzazioni Calabro-spanevello.ppt
• Altre pubblicazioni [PDF]

• 1) Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:446-452
• 2) Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:972-977
• 3) Kiri VA, Pride NB, Soriano JB, Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 2005;172:460-464
• 4) Stevenson NJ, Walker PP, Costello RW, Calverley PM. Lung Mechanics and Dyspnea during Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2005;172:1510-1516
• 5) Yasuda H, Yamaya M, Nakayama K, Ebihara S, Sasaki T, Okinaga S, Inoue D, Asada M, Nemoto M, Sasaki H. Increased arterial carboxyhemoglobin concentrations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:1246-1251
• 6) Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, Reznek RH, Wedzicha JA. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:400-7
• 7) Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA, Jr., Korducki L, Cassino C, Kesten S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143:317-26
• 8) Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73
• 9) Global Initiative for Chronic Obstructive Lung Disease. Update 1 July 2005. A collaborative project of the National Health L, and Blood Institute, NIH and the World Health Organisation., ed. www.goldcopd.org : National Institutes of Health, National Heart Lund and Blood Institute, Bethesda, Md, 2005.
• 10) Sin Don D., Lacy Paige, York Ernest, and Man S. F. Paul. Effects of Fluticasone on Systemic Markers of Inflammation in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med Vol 170. pp 760–765, 2004
• Altre pubblicazioni [PDF]

• Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL Patterns of Comorbidities in Newly Diagnosed COPD and Asthma in Primary Care Chest 2005;128;2099-2107 DOI: 10.1378/chest.128.4.2099
• Chronic Airways Diseases - A Guide for Primary Care Physicians - January 2005